Bristol-Myers Squibb's (BMY) new under-the-skin injection version of cancer drug Opdivo has received approval from the UK's Medicines and Healthcare products Regulatory Agency, the regulator said Wednesday.
The agency said the new version of the drug offers a "quicker administration option for eligible patients."
Common cancers like lung, bowel, kidney, bladder, oesophageal, skin, as well as head and neck cancers can be treated with Opdivo, the regulator said.
Bristol-Myers Squibb shares were up over 1% in recent trading.
Price: 49.80, Change: +0.58, Percent Change: +1.18
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.